⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

July 8, 2024The BreastOpen Access

Management and outcomes for older women with early breast cancer treated with primary endocrine therapy (PET)

Thomas Hubbard Georgia Wright Jenna Morgan Charlene Martin Stephen J. Walters Kwok‐Leung Cheung Riccardo A. Audisio Malcolm Reed Lynda Wyld

View Full Paper

Ask AI

Bookmark

Share

Abstract

This study reports the detailed management and outcomes of women treated with Primary Endocrine Therapy (PET) in a large prospective UK cohort of older women (≥70) with breast cancer.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Hubbard et al. (2024) studied this question.

synapsesocial.com/papers/68e61080b6db6435875a3564 https://doi.org/10.1016/j.breast.2024.103768

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1A UK national survey of breast surgeons on primary endocrine therapy of early operable breast cancerSurvey · 2013 · 26 citations
2973 Managing Primary Endocrine Treatment (PET) in Breast Cancer Patients: An Audit of Resource Utilisation and Risks2024
3Survival Outcomes in Older Women with Oestrogen-Receptor-Positive Early-Stage Breast Cancer: Primary Endocrine Therapy vs. Surgery by Comorbidity and Frailty Levels2024 · 1 citations
4The information and decision support needs of older women (>75 yrs) facing treatment choices for breast cancer: a qualitative studyDecision Analysis · 2014 · 54 citations
516P Determinants of response to short preoperative endocrine therapy (pET) in hormone receptor-positive and HER2-negative (HR+/HER2-) early breast cancer (EBC)2024

Initiation of Oral Endocrine Therapy and Survival Benefit Among Women with Early-Stage Breast Cancer2024
Abstract ED01-01: Optimizing endocrine therapy in premenopausal women2024
The relative efficacy of neoadjuvant endocrine therapy vs chemotherapy in postmenopausal women with ER- positive breast cancer2004
Belgian validation of the INFLUENCE 3.0 model predicting 5-year locoregional and contralateral breast cancer recurrenceThe Breast · 2026
Impact of Anti-HER2 Therapies on Potentially Avoidable Deaths from Stage II and III HER2-Positive Breast Cancer in the Brazilian Public Healthcare SystemThe Breast · 2026

More from The Breast

More from University of Sheffield

More from University of Nottingham

More from University of Exeter

More from Sahlgrenska University Hospital

More from Brighton and Sussex Medical School

More from Royal Devon and Exeter Hospital

More from Royal Derby Hospital